Study S002486

A Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profiles and Preliminary Efficacy of TQF3250 Capsules in Trial Participants With Type 2 Diabetes Mellitus Complicated With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07747857
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 72
Start: 2026-08-25
Primary completion: 2027-06
Lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions: Type 2 Diabetes Mellitus Combined With Overweight or Obesity
Interventions: DRUG:TQF3250 capsules; DRUG:TQF3250 placebo
Results posted: FALSE

Registered primary outcomes

Adverse Event [Baseline up to 14 weeks]
Abnormal clinical examination findings [Baseline up to 14 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.